Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.01M | 16.02M | 15.19M | 14.32M | 11.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.92M | 76.65M | 63.82M | 60.07M | 50.10M |
| Operating Income | -62.92M | -76.65M | -63.82M | -60.07M | -50.10M |
| Income Before Tax | -58.82M | -72.49M | -58.58M | -53.72M | -108.46M |
| Income Tax Expenses | 0.00 | 53.00K | 125.00K | -- | 268.00K |
| Earnings from Continuing Operations | -58.82M | -72.55M | -58.70M | -53.72M | -108.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.82M | -72.55M | -58.70M | -53.72M | -108.73M |
| EBIT | -62.92M | -76.65M | -63.82M | -60.07M | -50.10M |
| EBITDA | -62.77M | -76.49M | -63.66M | -59.92M | -49.93M |
| EPS Basic | -0.37 | -0.45 | -0.37 | -0.34 | -0.71 |
| Normalized Basic EPS | -0.23 | -0.28 | -0.23 | -0.21 | -0.18 |
| EPS Diluted | -0.37 | -0.45 | -0.37 | -0.34 | -0.71 |
| Normalized Diluted EPS | -0.23 | -0.28 | -0.23 | -0.21 | -0.18 |
| Average Basic Shares Outstanding | 160.98M | 159.58M | 158.98M | 157.94M | 152.83M |
| Average Diluted Shares Outstanding | 160.98M | 159.58M | 158.98M | 157.94M | 152.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
